Polypeptides isolated from brevibacterium aurantiacum and their use for the treatment of cancer
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite Paris Sud (Paris XI), INRA (Institut National de la Recherche Agronomique)
InventorsDavid Machover, Pascal Bonnarme
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and pharmaceutical compositions for treating cancer. More specifically, the invention relates to a polypeptide isolated from Brevibacterium aurantiacum that shows methionine gamma-lyase and homocysteinase activities. The present invention also relates to the use of such a polypeptide for the treatment of cancer.
Claims17
A polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof.
A nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof.
A vector comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof.
A host cell, which has been transformed by
- a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof
- and/or
- a vector comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof.
A method of producing a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1, which method comprises the steps of:
- i) culturing a host cell transformed by
- a) a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof,
- and/or
- b) a vector comprising a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof,
- under condition suitable to allow expression of said polypeptide;
- and
- (ii) recovering the expressed polypeptide.
A method for treating a cancer in a subject of need thereof comprising the step of administering to said subject a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof.
A method for treating a cancer in a subject of need thereof comprising the step of administering to said subject a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof.
A method for treating a cancer in a subject of need thereof comprising the step of administering to said subject a combination of
- i) a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof, or a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof,
- and
- ii) one or more agents selected from the group consisting of:
- one or more enzyme cofactors and one or more chemotherapeutic or radiotherapeutic agents.
(canceled)
A pharmaceutical composition comprising
- i) a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof, or a nucleic acid encoding a polypeptide comprising an amino acid sequence as set forth by SEQ ID NO:
- 1 or a functionally-conservative variant thereof,
- and
- ii) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.